Methoxsalen S.A.L.F. (Methoxsalen)

Methoxsalen intercalates between DNA base pairs and, after activation by UVA radiation, forms covalent cross‑links with pyrimidine residues. These cross‑links inhibit DNA replication and cell division, leading to reduced proliferation of keratinocytes and malignant T‑cells, and facilitating repigmentation in vitiligo through immunomodulation.

The dosage of methoxsalen is individualized by the prescribing clinician based on the specific indication, treatment protocol, and patient characteristics. Dosing may involve oral administration prior to UVA exposure or incorporation into extracorporeal photopheresis systems, and the exact amount and schedule are determined by the treating physician.

Safety data for methoxsalen in pregnancy and lactation are limited, and the drug is classified as having an unknown pregnancy category. It should only be used when the potential therapeutic benefit outweighs possible risks to the fetus or infant, and breastfeeding mothers should consult their healthcare provider before treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Methoxsalen S.A.L.F. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternative psoralens such as 8‑methoxypsoralen (trioxsalen), methoxsalen has a similar mechanism of DNA cross‑linking but differs in pharmacokinetic profile and regulatory approvals. Choice of agent depends on formulation availability, physician experience, and specific treatment protocols, with methoxsalen being widely used in PUVA and extracorporeal photopheresis.

Methoxsalen should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Maintaining these conditions helps preserve potency and prevents degradation, ensuring the product remains effective for clinical use.

Administration routes include oral ingestion prior to controlled UVA exposure in PUVA therapy, or incorporation into the treatment chamber of extracorporeal photopheresis devices. The exact method, timing, and dosage are determined by the treating clinician according to the selected therapeutic protocol.

The most critical risks include severe phototoxic burns from excessive UVA exposure, hemolysis in patients with glucose‑6‑phosphate dehydrogenase deficiency, and rare but life‑threatening allergic reactions such as anaphylaxis. Continuous monitoring during treatment and adherence to exposure guidelines help mitigate these hazards.

Contraindications include individuals with porphyria, severe hepatic impairment, known hypersensitivity to psoralens, and patients with G6PD deficiency due to the heightened risk of hemolysis. Additionally, pregnant or nursing women should avoid use unless the therapeutic benefit is clearly justified by a healthcare professional.